Innopharma Articles

Innopharma Technology Launches Eyecon₂™ Particle Size Analyser at POWTECH

DUBLIN, Ireland Apr, 19th  2016 – Innopharma Technology, today launches Eyecon2™,  a non-product contact particle characteriser of powder based processes for the pharmaceutical, chemical and food industries at the POWTECH conference in Nuremberg, Germany.

The Eyecon2 particle size analyser is used as a real-time, in-line or at-line particle size and shape monitoring process analytical technology (PAT) instrument. This unique system can be utilised for both batch and continuous processes, giving the user a deeper understanding of particle size distribution changes during processing and to allow process endpoint control based on particle size distribution (PSD) evaluation during formulation development, scale-up, technology transfer and commercial manufacturing. 

Eyecon2 which is launched today at POWTECH will also be showcased during April at INTERPHEX April 26-28 New York, and MAKING PHARMACEUTICALS April 26-27, Birmingham, UK. 

“Eyecon2 embodies the insights we have gained from working with customers in delivering PAT solutions over the last number of years” said Dr Ian Jones, CEO and founder of Innopharma Labs Ltd. “Eyecon2 represents a significant enhancement of our capability in using direct imaging methodology for particle size measurement in applications such as fluid bed coating (Wurster), granulation (fluid bed, twin screw, roller compaction), milling and spheronising“.

Eyecon2 is the latest addition to the Innopharma Technology PAT family. The instrument is housed in a compact, lightweight stainless steel casing with quick release cabling for ease of movement and cleaning.  Eyecon2 features a new optimised optical pathway resulting in improved field of view and a wider particle size measurement range.

Eyecon2 also features the new Eyepass™ software which allows the user to quickly set up the instrument to measure a process. Eyepass software provides powerful report generation including D-Values, PSD, and captured images of particles.  Eyepass also provides controls for U.S. FDA 21 CFR part 11compliance and data integration capability via commonly used open platform communications (OPC).